144 related articles for article (PubMed ID: 7842821)
21. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
Johnson DM; Jones RN
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of Ro 09-1428 compared to other cephalosporins.
Chin NX; Gu JW; Fang W; Neu HC
Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):669-75. PubMed ID: 1748124
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
[TBL] [Abstract][Full Text] [Related]
24. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins.
King A; Boothman C; Phillips I
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):677-85. PubMed ID: 2226498
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
29. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
30. In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China.
Wang H; Yu Y; Xie X; Wang C; Zhang Y; Yuan Y; Zhang X; Liu J; Wang P; Chen M
J Infect Chemother; 2000 Jun; 6(2):81-5. PubMed ID: 11810540
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.
Locher R; Strässle A; Kayser FH
Drugs Exp Clin Res; 1990; 16(10):515-25. PubMed ID: 2100734
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon.
Kanj SS; Chedid M; Araj GF
J Med Liban; 2001; 49(1):13-7. PubMed ID: 11910959
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.
Aldridge KE; Schiro DD; Sanders CV
Eur J Clin Microbiol; 1987 Oct; 6(5):564-9. PubMed ID: 3436316
[TBL] [Abstract][Full Text] [Related]
36. [Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to beta-lactamases].
Angelescu M; Apostol A
Chirurgia (Bucur); 2001; 96(6):547-52. PubMed ID: 12731231
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
39. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
